#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity

Boehringer Ingelheim's lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 diabetes. According to Endpoints News, this result trailed other candidates.

In comparison, Eli Lilly's investigational medication, a combination of eloralintide and tirzepatide, resulted in weight loss of up to 23.3% at the maximum dose, as reported by Medical Xpress. This study, presented at the European Association for the Study of Diabetes meeting in Milan, Italy, evaluated 367 adults with obesity or overweight and type 2 diabetes.

The study found substantial improvements in blood sugar control alongside the weight loss. Medical Xpress described eloralintide as a selective amylin receptor agonist and tirzepatide as a dual GIP/GLP-1 receptor agonist.

Brief written by urgent.news from Endpoints News, Medical Xpress — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.